Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01239316 · ClinicalTrials.gov registry record · Phase 2
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
A Phase 2 study of Recurrent Childhood Medulloblastoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 12
- Study locations
NCT01239316 is a Phase 2 study of Recurrent Childhood Medulloblastoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants, below the 54-participant average among 3 other Recurrent Childhood Medulloblastoma trials with a reported enrollment target (78% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT01239316, a Phase 2 study of Recurrent Childhood Medulloblastoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 12
- Study locations
Study Summary
This phase II trial studies how well vismodegib works in treating younger patients with recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Vismodegib
- OTHER Pharmacological Study
Study Locations (12)
California
- Children's Hospital Los Angeles - Los Angeles
- Lucile Packard Children's Hospital Stanford University - Palo Alto
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Lurie Children's Hospital-Chicago - Chicago
Maryland
- National Cancer Institute Pediatric Oncology Branch - Bethesda
New York
- Memorial Sloan-Kettering Cancer Center - New York
North Carolina
- Duke University Medical Center - Durham
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-11 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01239316
The ClinicalTrials.gov registry entry for NCT01239316 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 54-participant average among 3 other Recurrent Childhood Medulloblastoma trials with a reported enrollment target (78% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Childhood Medulloblastoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01239316 reports 12 study locations spanning 10 distinct geographic areas - top geographies include California, Pennsylvania, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01239316 about?
NCT01239316 is a clinical study titled "Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma". This phase II trial studies how well vismodegib works in treating younger patients with recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells.
What is the current status of trial NCT01239316?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2010-11. Estimated completion is 2015-08.
What conditions does trial NCT01239316 study?
This clinical trial studies the following conditions: Recurrent Childhood Medulloblastoma.
What interventions are being tested in trial NCT01239316?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Vismodegib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01239316?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01239316 being conducted?
This trial has 12 study locations across California, District of Columbia, Illinois, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Childhood Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
COMPLETED · Phase 2
-
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.